In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12477
Abstract: Polo‐like kinase 1 (Plk1), a master regulator of mitosis and the DNA damage response, is considered to be an intriguing target in the research field of mitotic intervention. The observation that Plk1 is overexpressed in… read more here.
Keywords: plk1; like kinase; volasertib; polo like ... See more keywords
Polo‐like kinase 4 inhibitor CFI‐400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology"
DOI: 10.1002/hep.32461
Abstract: Background and Aims: Prognosis of HCC remains poor due to lack of effective therapies. Immune checkpoint inhibitors (ICIs) have delayed response and are only effective in a subset of patients. Treatments that could effectively shrink… read more here.
Keywords: polo like; dna; inhibitor cfi; like kinase ... See more keywords
Functions and regulation of the Polo-like kinase Cdc5 in the absence and presence of DNA damage
Sign Up to like & getrecommendations! Published in 2017 at "Current Genetics"
DOI: 10.1007/s00294-017-0727-2
Abstract: Polo-like kinases are essential cell cycle regulators that are conserved from yeast to humans. Unlike higher eukaryotes, who express multiple Polo-like kinase family members that perform many important functions, budding yeast express only a single… read more here.
Keywords: dna damage; like kinase; cdc5; polo like ... See more keywords
Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2019.111769
Abstract: Polo-like kinase 1 (Plk1) is a validated target for the treatment of cancer. In this report, by analyzing amino acid residue differences among the ATP-binding pockets of Plk1, Plk2 and Plk3, novel selective Plk1 inhibitors… read more here.
Keywords: plk1; like kinase; plk1 inhibitors; polo like ... See more keywords
Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of biological macromolecules"
DOI: 10.1016/j.ijbiomac.2018.05.023
Abstract: Polo-like kinase-1 (PLK-1) plays a key role in cell cycle progression during mitosis. Overexpression/dysfunction of PLK-1 is directly associated with cancerous transformation and has been reported in different cancer types. Here, we employed high throughput… read more here.
Keywords: like kinase; kinase; polo like; hesperidin ... See more keywords
Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00614
Abstract: Polo-like kinase 1 (PLK1) plays an important role in a variety of cellular functions, including the regulation of mitosis, DNA replication, autophagy, and the epithelial-mesenchymal transition (EMT). PLK1 overexpression is often associated with cell proliferation… read more here.
Keywords: polo like; like kinase; development; therapy ... See more keywords
Human Polo-like Kinase Inhibitors as Antiplasmodials.
Sign Up to like & getrecommendations! Published in 2023 at "ACS infectious diseases"
DOI: 10.1021/acsinfecdis.3c00025
Abstract: Protein kinases have proven to be a very productive class of therapeutic targets, and over 90 inhibitors are currently in clinical use primarily for the treatment of cancer. Repurposing these inhibitors as antimalarials could provide… read more here.
Keywords: polo like; human polo; like kinase; kinase inhibitors ... See more keywords
Asterless is a Polo-like kinase 4 substrate that both activates and inhibits kinase activity depending on its phosphorylation state
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Biology of the Cell"
DOI: 10.1091/mbc.e18-07-0445
Abstract: Centriole assembly initiates when Polo-like kinase 4 (Plk4) interacts with a centriole “targeting-factor.” In Drosophila, Asterless/Asl (Cep152 in humans) fulfills the targeting role. Interestingly, Asl also regulates Plk4 levels. The N-terminus of Asl (Asl-A; amino… read more here.
Keywords: phosphorylation; plk4; kinase activity; kinase ... See more keywords
Pericentriolar matrix (PCM) integrity relies on cenexin and polo-like kinase (PLK)1
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Biology of the Cell"
DOI: 10.1091/mbc.e22-01-0015
Abstract: Polo-Like-Kinase (PLK) 1 activity is associated with maintaining the functional and physical properties of the centrosome’s pericentriolar matrix (PCM). In this study, we use a multimodal approach of human cells (HeLa) and zebrafish embryos in… read more here.
Keywords: polo like; like kinase; cenexin; pericentriolar matrix ... See more keywords
Polo-like kinase 4 homodimerization and condensate formation regulate its own protein levels but are not required for centriole assembly.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular biology of the cell"
DOI: 10.1091/mbc.e22-12-0572
Abstract: Polo-like kinase 4 (Plk4) is the master-regulator of centriole assembly and cell cycle-dependent regulation of its activity maintains proper centrosome number. During most of the cell cycle, Plk4 levels are nearly undetectable due to its… read more here.
Keywords: polo like; like kinase; centriole assembly; plk4 ... See more keywords
Polo-like kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz242.044
Abstract: Abstract Background Somatic mutation in TP53 gene (mutp53) is a strong prognostic marker in breast cancer. Triple negative breast cancer (TNBC) is characterized by up to 80% mutp53 and the greatest overall genomic instability among… read more here.
Keywords: breast; breast cancer; polo like; mutp53 ... See more keywords